Discussion about this post

User's avatar
John Stiller's avatar

Another excellent and perceptive piece. Dr. Love does a great job highlighting the extraordinary momentum in cancer treatment brought about by genetic engineering. The ability to reprogram the immune system, from ex vivo CAR T therapies to emerging in vivo approaches and CRISPR-edited TILs, represents a true leap forward in how we think about curing certain cancers rather than merely managing them.

What is especially encouraging is the way these technologies are beginning to converge: precise gene editing, enhanced targeting, and immune system reconditioning. The shift from custom-built cellular therapies to off-the-shelf or in vivo strategies could expand access dramatically while reducing cost and complexity.

We are witnessing a transition from proof of concept to scalable therapeutic innovation, and that is deeply hopeful. Of course, challenges remain, but the direction is unmistakably promising.

Expand full comment
Jim McMicking's avatar

Great stuff Dr. Love. I was a fan and supporter before this, but as a CAR T patient, now 2 years free of lymphoma, I appreciate the extra background info and comparative argument with ag science.

Expand full comment
4 more comments...

No posts